We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+54.5%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$583M
AUM Growth
+$84.1M
Cap. Flow
-$23.8M
Cap. Flow %
-4.08%
Top 10 Hldgs %
45.64%
Holding
119
New
32
Increased
28
Reduced
17
Closed
42

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$25.6M
2
ABVX
Abivax
ABVX
+$24.6M
3
TWST icon
Twist Bioscience
TWST
+$16.2M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$12.6M
5
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.9M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$63.7M
2
DNLI icon
Denali Therapeutics
DNLI
+$22.2M
3
IMVT icon
Immunovant
IMVT
+$21.1M
4
QURE icon
uniQure
QURE
+$18.5M
5
WVE icon
Wave Life Sciences
WVE
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLPT icon
26
ClearPoint Neuro
CLPT
$454M
$6.59M 1.13%
481,858
+465,207
+2,794% +$8.62M
ARQT icon
27
Arcutis Biotherapeutics
ARQT
$3.56B
$6.53M 1.12%
224,740
-187,153
-45% -$4.79M
EYPT icon
28
EyePoint Inc
EYPT
$1.12B
$6.46M 1.11%
+353,849
New +$5.01M
IMTX icon
29
Immatics
IMTX
$1.31B
$6.41M 1.1%
+610,308
New +$6.16M
OCUL icon
30
Ocular Therapeutix
OCUL
$1.96B
$6.35M 1.09%
522,693
+163,223
+45% +$1.98M
RYTM icon
31
Rhythm Pharmaceuticals
RYTM
$7.31B
$6.31M 1.08%
58,915
-32,529
-36% -$3.45M
PRAX icon
32
Praxis Precision Medicines
PRAX
$8.77B
$6.21M 1.06%
+21,067
New +$3.92M
APGE icon
33
Apogee Therapeutics
APGE
$10.1B
$6.08M 1.04%
+80,574
New +$5.08M
INCY icon
34
Incyte
INCY
$23.4B
$6.07M 1.04%
61,435
+17,681
+40% +$1.71M
IDYA icon
35
IDEAYA Biosciences
IDYA
$3.47B
$5.59M 0.96%
161,659
-210,166
-57% -$6.7M
ASMB icon
36
Assembly Biosciences
ASMB
$531M
$5.33M 0.91%
156,728
+90,598
+137% +$2.92M
MAZE
37
Maze Therapeutics
MAZE
$1.56B
$5.22M 0.89%
+125,877
New +$4.33M
PTGX icon
38
Protagonist Therapeutics
PTGX
$9.06B
$5.19M 0.89%
59,430
+11,476
+24% +$939K
LLY icon
39
Eli Lilly
LLY
$1.05T
$5.11M 0.88%
+4,759
New +$4.55M
TRVI icon
40
Trevi Therapeutics
TRVI
$2.71B
$5M 0.86%
399,557
+48,847
+14% +$565K
RVMD icon
41
Revolution Medicines
RVMD
$39.6B
$4.94M 0.85%
62,032
-123,348
-67% -$8.09M
VRDN icon
42
Viridian Therapeutics
VRDN
$1.99B
$4.8M 0.82%
+154,320
New +$4.23M
ABUS icon
43
Arbutus Biopharma
ABUS
$901M
$4.75M 0.81%
986,751
+781,363
+380% +$3.51M
MLTX icon
44
MoonLake Immunotherapeutics
MLTX
$1.64B
$4.59M 0.79%
+348,401
New +$4.11M
CTMX icon
45
CytomX Therapeutics
CTMX
$788M
$4.41M 0.76%
+1,036,311
New +$3.94M
XFOR icon
46
X4 Pharmaceuticals
XFOR
$360M
$3.59M 0.62%
898,465
+343,054
+62% +$1.25M
WHWK
47
Whitehawk Therapeutics
WHWK
$192M
$3.53M 0.61%
1,458,807
+1,034,725
+244% +$2.37M
DNTH icon
48
Dianthus Therapeutics
DNTH
$5.77B
$3.27M 0.56%
79,284
+37,902
+92% +$1.47M
ASND icon
49
Ascendis Pharma A/S
ASND
$17.1B
$3.16M 0.54%
14,842
-307
-2% -$63.4K
RGEN icon
50
Repligen
RGEN
$8.31B
$2.57M 0.44%
+15,707
New +$2.46M
1
2
3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Stempoint Capital held 119 positions worth $583M, up 17% from $499M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Stempoint Capital withdrew a net $23.8M in Q4 2025, closing 42 positions and reducing 17 holdings. Its most notable exit was Wave Life Sciences, an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Twist Bioscience worth $16.4M.

  • Stempoint Capital's largest Q4 2025 buy was Twist Bioscience: 518,355 shares worth $16.4M.
  • Stempoint Capital added most to Arcellx in Q4 2025, an estimated $25.6M increase.
  • Stempoint Capital's biggest Q4 2025 reduction was Roivant Sciences, cutting an estimated $63.7M.
  • Stempoint Capital fully exited Wave Life Sciences in Q4 2025, selling an estimated $15.4M.
  • Stempoint Capital's ten largest holdings make up 46% of its $583M portfolio in Q4 2025.
  • Stempoint Capital opened 32 new positions and closed 42 in Q4 2025.
  • Stempoint Capital's portfolio value rose 17% quarter-over-quarter to $583M.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.